Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MET positive
i
Other names:
DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4233
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
MET overexpression (32)
MET expression (12)
EGFR expression + MET expression (2)
MET overexpression + KDR overexpression (2)
MET overexpression + SYK overexpression (2)
TPBG expression + MET expression (2)
FGFR overexpression + MET overexpression (1)
MET expression + HER-2 expression (1)
MET overexpression + HER-2 overexpression (1)
MET overexpression + MUC5B overexpression (1)
MET underexpression (1)
PTGS2 positive + MET positive + TOPK positive + EGFR mutation (0)
MET overexpression (32)
MET expression (12)
EGFR expression + MET expression (2)
MET overexpression + KDR overexpression (2)
MET overexpression + SYK overexpression (2)
TPBG expression + MET expression (2)
FGFR overexpression + MET overexpression (1)
MET expression + HER-2 expression (1)
MET overexpression + HER-2 overexpression (1)
MET overexpression + MUC5B overexpression (1)
MET underexpression (1)
PTGS2 positive + MET positive + TOPK positive + EGFR mutation (0)
›
Associations
(8)
News
Trials
Search handles
Search handles
Filter by
Latest
10ms
In a biomarker analysis of cohort D in the CHRYSALIS-2 trial, patients with MET-positive NSCLC achieved an ORR of 61% with amivantamab plus lazertinib vs an ORR of 14% in the MET-negative population. @BenjaminBesseMD @GustaveRoussy @ASCO #ASCO23 #lcsm https://t.co/NsJLrnBlf5 (@OncLive)
10 months ago
Clinical
|
MET positive
|
Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
1year
The risk of brain metastasis in TNBC and HER2 positive met breast cancer is between 25-45%. We need data and trials to address this. We are working in this and DM if interested. (@MaheshIddawela)
1 year ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • MET positive
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login